Market Overview

New Studies Confirm Value of Given Imaging's Advanced Esophageal Diagnostics Products in Diagnosing and Monitoring Esophageal Disorders


Given Imaging (NASDAQ: GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that new studies confirm the value of its PillCam ESO as a tool to help triage patients with upper gastrointestinal bleeding and show that PillCam ESO can detect lesions that traditional gastroscopy has missed.

An additional new study shows that Bravo pH monitoring for patients with gastroesophageal reflux disease can be extended to four days to increase findings. This longer duration will result in more meaningful feedback regarding patients' conditions and how they are affected by daily activities, allowing doctors to work with patients to adjust their diet and drug regimens. The data from these studies were presented at Digestive Disease Week, being held from May 19-22, 2012, in San Diego.

"These new studies confirm the clinical efficacy of PillCam ESO and Bravo pH monitoring in diagnosing, monitoring, and triaging a variety of esophageal disorders," said David Mason, MD, Chief Medical Officer at Given Imaging. "PillCam ESO has been shown to be useful in detecting lesions which if not quickly found could result in serious or fatal bleeding in the upper GI tract and in detecting lesions that gastroscopy was not able to pick up. Additionally, Bravo pH monitoring helped to successfully monitor and stratify cases of gastroesophageal reflux disease."

Posted-In: News FDA General


Related Articles (GIVN)

View Comments and Join the Discussion!